Cefpodoxime

A third-generation cephalosporin antibiotic. Cefpodoxime contains a methoxy group at C-3 of its cephalosporin core.

Also Known As:

R 3746; R-3746; RU 51746; RU-51746; U 76253A; U-76,253A; 3746, R; 51746, RU; 76253A, U; R3746; RU51746; Salt, Cefpodoxime Sodium; Sodium Salt, Cefpodoxime; Sodium, Cefpodoxime; U 76,253A; U76,253A; 5-Thia-1-Azabicyclo(4.2.0)oct-2-ene-2-Carboxylic Acid, 7-(((2-Amino-4-Thiazolyl)(Methoxyimino)Acetyl)Amino)-3-(Methoxymethyl)-8-oxo-, Monosodium Salt, (6R-(6alpha,7beta(Z)))-; Cefpodoxime Sodium; Cefpodoxime Sodium Salt

Networked: 114 relevant articles (13 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cohen, Robert: 2 articles (10/2021 - 07/2002)
2.	Kranz, Jennifer: 2 articles (01/2018 - 12/2017)
3.	Lebert, Cordula: 2 articles (01/2018 - 12/2017)
4.	Schmidt, Stefanie: 2 articles (01/2018 - 12/2017)
5.	Schmiemann, Guido: 2 articles (01/2018 - 12/2017)
6.	Schneidewind, Laila: 2 articles (01/2018 - 12/2017)
7.	Ghosh, Arijit: 2 articles (06/2017 - 10/2012)
8.	Pichichero, Michael E: 2 articles (02/2006 - 04/2005)
9.	Gupta, Aanchal: 1 article (04/2022)
10.	Kaminski, Monica: 1 article (04/2022)

Related Diseases

1.	Infections 01/01/2010 - "There are limited data on the efficacy of cefpodoxime for the treatment of uncomplicated gonococcal infections. " 04/01/2011 - "High urine concentrations suggested cefpodoxime use for urinary infections in dogs." 04/01/2011 - "Comparison of subcutaneous fluid concentrations using pharmacokinetic/pharmacodynamic indices of fT(>MIC) indicated that at 10 mg/kg dose; cefpodoxime would yield good therapeutic outcome in skin infections for bacteria with MIC(50) upto 0.5 μg/mL while higher doses (or more frequent dosing) may be needed for bacteria with higher MICs. " 11/01/1993 - "Cefpodoxime demonstrates good in vitro activity against pathogens frequently associated with respiratory tract, urinary tract, and skin and tissue infections. " 01/01/1992 - "Adjustments in cefpodoxime organism and on the site and severity of infection. "
2.	Sinusitis 07/01/2002 - "Clinical studies confirm the efficacy of cefpodoxime in AOM, sinusitis and tonsillopharyngitis. " 05/01/2004 - "Clinical studies have confirmed efficacy of cefpodoxime in acute otitis media, sinusitis and tosillopharyngitis. " 02/01/2002 - "Treatment guidelines for acute bacterial sinusitis recommend 10 to 14 days of therapy with amoxicillin/clavulanate, high-dose amoxicillin, cefpodoxime, cefuroxime, or a newer fluoroquinolone. " 04/01/2007 - "Prospective, multicenter, randomized, double-blind, comparative (not vs placebo) clinical trials of acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) and uncomplicated skin and skin structure infections (uSSSIs) have demonstrated that faropenem medoxomil has equivalent efficacy and safety compared with cefuroxime, clarithromycin, azithromycin, amoxicillin, cefpodoxime and amoxicillin-clavulanate. " 04/01/2005 - "The antimicrobials that are the most effective in management of acute sinusitis are amoxycillin-clavulanate (given in a high dose), the newer quinolones (gatifloxacin, moxifloxacin) and the second generation cephalosporins (cefuroxime, cefpodoxime, cefprozil or cefdinir). "
3.	Respiratory Tract Infections (Respiratory Tract Infection) 08/01/1993 - "Cefpodoxime was very effective against the fastidious organisms most frequently associated with respiratory infections, such as Streptococcus pneumoniae (MIC90, 0.12 microgram/ml), Haemophilus influenzae (MIC90, 0.12 microgram/ml), and Moraxella catarrhalis (MIC90, 1 microgram/ml). " 01/01/1991 - "Cefpodoxime appears to be an effective new antibacterial that can be recommended as a drug of first choice in the treatment of most upper respiratory tract infections." 07/01/2002 - "Clinical efficacy of cefpodoxime in respiratory tract infection." 07/01/2002 - "These data indicate that cefpodoxime represents an appropriate choice in the treatment of community-acquired respiratory tract infection in the three countries surveyed." 01/01/1993 - "Cefpodoxime (CPDX-PR) was evaluated clinically in respiratory tract infections. "
4.	Otitis Media 01/01/1997 - "Penetration of cefpodoxime into middle ear fluid in pediatric patients with acute otitis media." 03/04/1994 - "A high-performance liquid chromatographic method has been developed to determine cefpodoxime levels in chinchilla plasma and middle ear fluid (MEF) to be used in studying otitis media. " 11/01/1993 - "Cefpodoxime is well tolerated by children and is effective in the treatment of otitis media and pharyngitis. " 05/01/2004 - "Clinical studies have confirmed efficacy of cefpodoxime in acute otitis media, sinusitis and tosillopharyngitis. " 09/01/1998 - "We conclude that cefpodoxime administered once daily is as effective and safe as cefaclor administered thrice daily in the treatment of acute otitis media in children. "
5.	Pharyngitis (Sore Throat) 09/01/1991 - "The Cefpodoxime Pharyngitis Study Group." 11/01/1993 - "Cefpodoxime is well tolerated by children and is effective in the treatment of otitis media and pharyngitis. " 08/01/1998 - "(1) Oral cefpodoxime, a third-generation cephalosporin, has a reduced treatment duration for recurrent pharyngitis; but this is based on a single unblinded trial. " 01/01/2001 - "Cefpodoxime 8 to 10 mg/kg/day (administered in 2 divided doses) for 5 to 10 days was at least as effective as standard 10-day regimens of penicillin V in the treatment of children with pharyngitis and/or tonsillitis. "

Related Drugs and Biologics

1.	Clavulanic Acid (Potassium Clavulanate)
2.	Cefaclor (Ceclor)
3.	Cefpodoxime Proxetil (Vantin)
4.	Amoxicillin (Wymox)
5.	Cephalosporins (Cephalosporin Antibiotics)
6.	Penicillin V (Phenoxymethylpenicillin)
7.	Cefuroxime (Zinacef)
8.	Penicillins (Penicillin)
9.	Anti-Bacterial Agents (Antibiotics)
10.	Cefixime (Suprax)

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Drug Therapy (Chemotherapy)
4.	Oral Administration
5.	Duration of Therapy